Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
about
Interventions for fatigue in Parkinson's diseaseMonoamine oxidase B inhibitors for early Parkinson's diseaseMAO-inhibitors in Parkinson's DiseaseCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyTherapeutic directions for Parkinson's diseaseReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.Astrocytes and therapeutics for Parkinson's disease.Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.Antioxidants as treatment for neurodegenerative disorders.Medical management of Parkinson's disease: focus on neuroprotectionOxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics.Present and future drug treatment for Parkinson's disease.Rationale for current therapies in Parkinson's disease.2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.Neurodegeneration and neuroprotection in Parkinson disease.Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.New therapeutic approaches to Parkinson's disease including neural transplants.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsParkinson's disease management strategies.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Current approaches to the treatment of Parkinson's diseaseFreezing of Gait in Parkinsonism and its Potential Drug Treatment.Amantadine for freezing of gait in patients with Parkinson diseaseZydis selegiline in the management of Parkinson's disease.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.A review of disease progression models of Parkinson's disease and applications in clinical trialsProgress in neuroprotection in Parkinson's disease.Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson diseaseMinority enrollment in Parkinson's disease clinical trials.Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort StudyDual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseIncidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.How should we treat a patient with early Parkinson's disease?Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Safety of rasagiline for the treatment of Parkinson's disease.Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
P2860
Q24186581-85E6397F-05D2-4834-B18F-CFE225BE027BQ24246514-F16E1D28-AB1E-4C8F-820E-8DE694108B27Q24629770-9015B600-3475-41B9-BBD9-958FBA4F6AB1Q24644555-00D09B0E-60FE-48C5-BD9B-1377B7FC10ADQ28069609-339A76A2-1C57-4702-B504-37F13A0DAD02Q28743874-1ACB84C5-70D5-41F1-BE4D-D7AE2D8EAFD6Q33260250-B6BC856B-2C08-49E7-8725-B56E84B9438BQ33260251-0BA3AE96-E9BC-431D-91EE-9282EEB5FC1AQ33765388-41F6CB7E-1045-48EF-BA74-61C6168E63EEQ34168266-5DCEF10B-E932-4B82-9359-E793D370E3DAQ34306751-91C8D8E9-CF45-4D48-BF8B-6F51D4F6226CQ34974866-F2A8FC08-26B0-42E5-B964-03243BADACD6Q35092165-895523E5-260C-4AA1-85BB-E1C176DDEC9BQ35116171-5B8507F8-09BE-4283-AF42-CAC7AA015BF8Q35484805-ADDEB455-01A9-4F4E-ACD1-2B5FE8C6F831Q35548168-621138F1-52EA-4CB1-B710-321F662FA441Q35867089-F0B9C790-2265-4DAB-83A6-A45BA128914AQ36045259-D1BCFE39-27A4-40DA-939B-4168E1A14407Q36164724-9C6B7253-29D2-44F4-92BE-096595F829FBQ36225073-2B82A0AF-EEC8-41A2-8E2A-7FC4D87C3548Q36251899-63AD3414-4761-4679-8933-945B6BC064C8Q36390875-EB74E19C-1F7C-4C8F-BE61-09A5C516C779Q36499640-49A38A34-7CF1-4583-B943-D8F41388E222Q36876438-BB72BDCB-4296-422A-AE48-BCDEC22CF3DFQ36925884-FD6FF102-004C-4E65-A814-0044E9657785Q36948725-26C88369-D0FB-417C-ADDE-9D11A522A840Q36968199-3464911F-F4A3-4984-8059-929EDACB6C3CQ37016034-C324B4C2-D900-485D-BB86-8EC976FC7786Q37062838-D82C2771-6953-485E-A9E8-5F6A06DFCE93Q37114112-E88EB337-3568-4B03-A6C9-3F55EC8777C3Q37228718-7AA856D1-D317-4794-967B-490313A4E957Q37236732-F497FDAF-8518-49F6-B88D-3F5A58A77DDBQ37279146-1F4F0934-0AB5-404F-87C5-9CA932742CA6Q37358676-BCD70C6D-18EE-4122-A9E8-078B4BD1F033Q37425084-0B190AD7-FE77-4D5D-AE05-DE0E6F3DDFD3Q37775098-15FF07B1-FC20-4E31-8D0F-58F0D8BDBC5DQ37855572-F7D3C1DE-12FA-4DE4-8A6F-824D7EB4EE9CQ37859776-B91EB42A-1F53-41BA-9229-4E756F3CCC8FQ37865446-7D87147F-EF69-4D6F-9A43-24F0FB18DD03Q37963572-6DF414EE-5280-42DD-BD1A-BA08F6BA7906
P2860
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Impact of sustained deprenyl ( ...... therapy of parkinsonism trial.
@en
Impact of sustained deprenyl
@nl
type
label
Impact of sustained deprenyl ( ...... therapy of parkinsonism trial.
@en
Impact of sustained deprenyl
@nl
prefLabel
Impact of sustained deprenyl ( ...... therapy of parkinsonism trial.
@en
Impact of sustained deprenyl
@nl
P2093
P2860
P50
P356
P1433
P1476
Impact of sustained deprenyl ( ...... therapy of parkinsonism trial.
@en
P2093
Alice Rudolph
David Oakes
Ira Shoulson
J William Langston
John B Penney
Parkinson Study Group
Peter LeWitt
P2860
P304
P356
10.1002/ANA.10191
P577
2002-05-01T00:00:00Z